Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Cells , 10 (6), 1343
Recent Mergers & Acquisitions (M & A) 2025-2026: Mar 2026: BioMarin Pharmaceutical agreed to acquire rare disease biotech Amicus Therapeutics for $4.8B, strengthening metabolic & rare disease franchise overlap with diabetes-associated disorders Mar 2026: Sanofi entered $2.2B acquisition deal for Dynavax Technologies to expand vaccine and immunometabolic pipeline supporting diabetes-comorbidity therapeutics Jan 2026: Eli Lilly and Company announced acquisition of Ventyx Biosciences for $1.2B, expanding cardiometabolic and diabetes-related pipeline into immunology-linked therapies 2026 (closed/announced): Merck & Co
One of the biggest challenges in all of this is getting a successful remediation done, she said
IOLs were one of the first successful long-term medical implants due to the immune systems general tolerance for the plastics used (6870)
In clinical studies, people taking this drug lost 15-22.5% of their body weight over 72 weeks
